What insurance policy changes affect code M06.4?

There are 4 tracked policy changes affecting code M06.4, including updates from Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M06.4?

Payers that have issued tracked updates for code M06.4 include: Independence Blue Cross, Aetna.

How do I get notified when code M06.4 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M06.4. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M06.4?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

M06.4 Insurance Policy Changes

ICD-10 M06.4 is officially defined as "Inflammatory polyarthropathy." code M06.4 is referenced in 4 tracked payer policy changes from Independence Blue Cross and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M06.4 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Sep 21, 2026Medium impact
MA08.045r, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Independence Blue Cross Medicare Advantage revised its tocilizumab policy (MA08.045r), effective and applied retroactively to September 21, 2026, to update criteria for cytokine release syndrome, immunotherapy toxicity and CAR T-cell neurotoxicity, add Kaposi sarcoma-associated inflammatory cytokine syndrome criteria, and revise the systemic juvenile idiopathic arthritis criteria. It also adds a long list of ICD-10 diagnosis codes as medically necessary, including groups M05, M06, C46, C90, C91, D47.Z2, D89.8 and G92.0.
Independence Blue Cross · Effective Oct 1, 2025Medium impact
MA08.070g, Golimumab (Simponi Aria®) Intravenous (IV) Injection
Independence Blue Cross Medicare Advantage policy MA08.070g for Golimumab (Simponi Aria IV) has been updated with a new ICD-10 diagnosis code M05.A (Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis) effective 10/01/2025. Billing teams must ensure claims for golimumab IV injection include this newly added diagnosis code to support medical necessity for rheumatoid arthritis cases.
Independence Blue Cross · Effective Oct 1, 2025Medium impact
08.01.15h, Golimumab (Simponi Aria®) Intravenous (IV) Injection
Independence Blue Cross updated policy 08.01.15h for Golimumab (Simponi Aria IV) effective 10/01/2025, adding new ICD-10 code M05.A for abnormal rheumatoid factor/anti-citrullinated protein antibody with rheumatoid arthritis, and removing numerous M05 and M06 codes (except M06.4) due to unspecified laterality. Billing teams must update diagnosis code validation rules to reflect these changes and ensure prior authorization aligns with the updated covered indications.
Aetna · Identified Aug 16, 2026Medium impact
Rheumatic Diseases: Selected Tests (CPB 0866, reviewed 2025-12-22)
Aetna considers HLA-B27 testing medically necessary for diagnosing ankylosing spondylitis and Reiter's syndrome (reactive arthritis), anti-CCP antibodies medically necessary for diagnosing rheumatoid arthritis, a myositis antibody panel medically necessary for diagnosing inflammatory myopathy, and anti-dsDNA antibodies medically necessary for evaluating and managing systemic lupus erythematosus. The UBA1 mutation test (QClamp Plex VEXAS) is medically necessary for detecting VEXAS syndrome in individuals aged 18 years or older who present with clinical features of the syndrome. Aetna considers the listed biomarker tests experimental, investigational or unproven because their effectiveness has not been established, including the aiSLE DX indices, PrismRA, Vectra DA, the Avise tests, anti-MCV antibodies, the Early Sjogren's Syndrome Profile, and anti-CCP antibodies for indications other than rheumatoid arthritis.

Watch M06.4

Get one email when a payer policy names M06.4, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA08.045r, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection

MA08.070g, Golimumab (Simponi Aria®) Intravenous (IV) Injection

08.01.15h, Golimumab (Simponi Aria®) Intravenous (IV) Injection

Rheumatic Diseases: Selected Tests (CPB 0866, reviewed 2025-12-22)

What insurance policy changes affect code M06.4?

Which payers have updated policy for code M06.4?

How do I get notified when code M06.4 policy changes?

Why do payers change policies for code M06.4?